Re: FMI
"Let us try to compare FMI/ Biocept from the product perspective."
Difficult comparison, and perhaps a bit like comparing an atomic bomb to a sniper rifle. The intent of each offering somewhat different, with Target Selector being utilized for it's cost effectiveness in confirming suspected targets. From a payors' standpoint, an important consideration in a post-diagnostic setting, after disease presence and initial targeting has already been confirmed by shotgun analysis of blood and tissue sampling. I would suggest that a comparative cost analysis of Target Selector would make it a best choice for ongoing monitoring of treatment effectivity, disease progression, and/or onset of treatment resistance.
It's always difficult comparing Jack to the giant...especially when the beanstalk is as yet a mere sprout.